Literature DB >> 12745543

Correlation of serum tumor necrosis factor-alpha, interleukin-4 and soluble interleukin-2 receptor levels with radiologic and clinical manifestations in active pulmonary tuberculosis.

Levent Kart1, Hakan Buyukoglan, Ishak O Tekin, Remzi Altin, Zuhal Senturk, Inci Gulmez, Ramazan Demir, Mustafa Ozesmi.   

Abstract

The precise clinical manifestations of tuberculosis are likely to result from a complex interaction between the host and the pathogen. We took serum samples from a group of patients with a variety of clinical and radiological stages of pulmonary tuberculosis in order to characterize tumor necrosis factor-alpha (TNF-alpha), interleukin-4 (IL-4) and soluble interleukin-2 receptor (sIL-2R) response. We further evaluated whether the levels of TNF-alpha, IL-4 and soluble IL-2R are related with each other, and also evaluated the levels of TNF-alpha, IL-4 and sIL-2R after anti-tuberculosis therapy and relation with radiologic scores. Forty-three inpatients with active pulmonary tuberculosis and 19 healthy controls participated in the study. Patients were divided into four categories radiologically on chest X-ray (minimal, moderate-advanced, far-advanced and with miliary infiltration). Concentrations of TNF-alpha (20.9+/-10/15.4+/-8 pg/ml) and sIL-2R (2569+/-842/1444+/-514 pg/ml) were statistically different between patients and controls (p=0.02 and p=0.0001, respectively). Before chemotherapy there was a positive correlation between TNF-alpha and sIL-2R (r=0.34), but there was no correlation between IL-4 and TNF-alpha, and between IL-4 and sIL-2R (r=-0.23 and r=-0.22). The TNF-alpha level was not statistically different in four groups before and after chemotherapy. Results of this study provided some evidence confirming the previously reported role of TNF-alpha, IL-4 and sIL 2R in the control of tuberculosis, but these cytokines were not found related with disease severity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12745543      PMCID: PMC1781590          DOI: 10.1080/0962935031000096926

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  36 in total

1.  CD8- and CD95/95L-dependent mechanisms of resistance in mice with chronic pulmonary tuberculosis.

Authors:  J Turner; C D D'Souza; J E Pearl; P Marietta; M Noel; A A Frank; R Appelberg; I M Orme; A M Cooper
Journal:  Am J Respir Cell Mol Biol       Date:  2001-02       Impact factor: 6.914

Review 2.  Proinflammatory cytokines.

Authors:  C A Dinarello
Journal:  Chest       Date:  2000-08       Impact factor: 9.410

3.  The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis.

Authors:  I M Orme
Journal:  J Immunol       Date:  1987-01-01       Impact factor: 5.422

4.  Serum levels of vascular endothelial growth factor and cavity formation in active pulmonary tuberculosis.

Authors:  Y Abe; M Nakamura; Y Oshika; H Hatanaka; T Tokunaga; Y Ohkubo; T Hashizume; K Suzuki; T Fujino
Journal:  Respiration       Date:  2001       Impact factor: 3.580

5.  Increased production of interleukin 4 by CD4+ and CD8+ T cells from patients with tuberculosis is related to the presence of pulmonary cavities.

Authors:  R van Crevel; E Karyadi; F Preyers; M Leenders; B J Kullberg; R H Nelwan; J W van der Meer
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

6.  Early emergence of CD8(+) T cells primed for production of type 1 cytokines in the lungs of Mycobacterium tuberculosis-infected mice.

Authors:  N V Serbina; J L Flynn
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

7.  Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis.

Authors:  G T Seah; G M Scott; G A Rook
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

Review 8.  Immunopathogenesis of delayed-type hypersensitivity.

Authors:  K Kobayashi; K Kaneda; T Kasama
Journal:  Microsc Res Tech       Date:  2001-05-15       Impact factor: 2.769

9.  Sputum cytokine levels in patients with pulmonary tuberculosis as early markers of mycobacterial clearance.

Authors:  Rodrigo Ribeiro-Rodrigues; Tatiana Resende Co; John L Johnson; Fabiola Ribeiro; Moises Palaci; Ricardo T Sá; Ethel L Maciel; Fausto E Pereira Lima; Valderio Dettoni; Zahra Toossi; W Henry Boom; Reynaldo Dietze; Jerrold J Ellner; Christina S Hirsch
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

10.  Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex.

Authors:  L E Bermudez; L S Young
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

View more
  7 in total

1.  Mycobacterium tuberculosis-stimulated whole blood culture to detect host biosignatures for tuberculosis treatment response.

Authors:  Karen Cilliers; Angela Menezes; Tariq Webber; Hazel M Dockrell; Jacqueline M Cliff; Léanie Kleynhans; Novel N Chegou; Nelita du Plessis; André G Loxton; Martin Kidd; Joel Fleury Djoba Siawaya; Katharina Ronacher; Gerhard Walzl
Journal:  Tuberculosis (Edinb)       Date:  2021-04-10       Impact factor: 3.131

2.  Changes in serum cytokine levels in active tuberculosis with treatment.

Authors:  Figen Deveci; H Handan Akbulut; Teyfik Turgut; M Hamdi Muz
Journal:  Mediators Inflamm       Date:  2005-10-24       Impact factor: 4.711

3.  Evaluation of TNF-α, IL-10 and IL-6 Cytokine Production and Their Correlation with Genotype Variants amongst Tuberculosis Patients and Their Household Contacts.

Authors:  Lavanya Joshi; Meenakshi Ponnana; Ramya Sivangala; Lakshmi Kiran Chelluri; Prathiba Nallari; Sitaramaraju Penmetsa; Vijayalakshmi Valluri; Sumanlatha Gaddam
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

4.  A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis.

Authors:  Selena Ferrian; Claudia Manca; Sugnet Lubbe; Francesca Conradie; Nazir Ismail; Gilla Kaplan; Clive M Gray; Dorothy Fallows
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.240

5.  Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment.

Authors:  Sasha E Larsen; Susan L Baldwin; Mark T Orr; Valerie A Reese; Tiffany Pecor; Brian Granger; Natasha Dubois Cauwelaert; Brendan K Podell; Rhea N Coler
Journal:  Vaccines (Basel)       Date:  2018-05-24

Review 6.  The effects of twenty-four nutrients and phytonutrients on immune system function and inflammation: A narrative review.

Authors:  Jillian Poles; Elisa Karhu; Megan McGill; H Reginald McDaniel; John E Lewis
Journal:  J Clin Transl Res       Date:  2021-05-27

7.  The pathogen recognition sensor, NOD2, is variably expressed in patients with pulmonary tuberculosis.

Authors:  Sanjay Lala; Keertan Dheda; Jung-Su Chang; Jim F Huggett; Louise U Kim; Margaret A Johnson; Graham A W Rook; Satish Keshav; Alimuddin Zumla
Journal:  BMC Infect Dis       Date:  2007-08-16       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.